Pneumococcal vaccination for cochlear implant candidates and recipients: updated recommendations of the Advisory Committee on Immunization Practices.
In October 2002, CDC recommended that all persons with cochlear implants receive age-appropriate pneumococcal vaccination with 7-valent pneumococcal conjugate vaccine (PCV7) (Prevnar), 23-valent pneumococcal polysaccharide vaccine (PPV23) (Pneumovax), or both according to the Advisory Committee on Immunization Practices (ACIP) schedules for persons at high risk. CDC issued these recommendations on the basis of preliminary data suggesting an increased risk for pneumococcal meningitis in persons with cochlear implants. Findings of a recent investigation by CDC, the Food and Drug Administration (FDA), and state health departments support this recommendation. Children aged <6 years with a cochlear implant had a substantially greater risk for having pneumococcal meningitis, compared with children in the general U.S. population of the same age. Some children who are candidates for cochlear implants have pre-existing anatomic factors that might contribute to an increased risk for meningitis; however, the recent study was not designed to assess this association.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003054:Cochlear Implants; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008875:Middle Aged; D022242:Pneumococcal Vaccines / Q000008:administration & dosage*
D022242:Pneumococcal Vaccines